Cargando…

Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome

Fragile X syndrome (FXS) is characteristically displayed intellectual disability, hyperactivity, anxiety, and abnormal sensory processing. Electroencephalography (EEG) abnormalities are also observed in subjects with FXS, with many researchers paying attention to these as biomarkers. Despite intensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kozono, Naoki, Okamura, Ai, Honda, Sokichi, Matsumoto, Mitsuyuki, Mihara, Takuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608556/
https://www.ncbi.nlm.nih.gov/pubmed/33139785
http://dx.doi.org/10.1038/s41598-020-75893-x
_version_ 1783604861234839552
author Kozono, Naoki
Okamura, Ai
Honda, Sokichi
Matsumoto, Mitsuyuki
Mihara, Takuma
author_facet Kozono, Naoki
Okamura, Ai
Honda, Sokichi
Matsumoto, Mitsuyuki
Mihara, Takuma
author_sort Kozono, Naoki
collection PubMed
description Fragile X syndrome (FXS) is characteristically displayed intellectual disability, hyperactivity, anxiety, and abnormal sensory processing. Electroencephalography (EEG) abnormalities are also observed in subjects with FXS, with many researchers paying attention to these as biomarkers. Despite intensive preclinical research using Fmr1 knock out (KO) mice, an effective treatment for FXS has yet to be developed. Here, we examined Fmr1-targeted transgenic rats (Fmr1-KO rats) as an alternative preclinical model of FXS. We characterized the EEG phenotypes of Fmr1-KO rats by measuring basal EEG power and auditory steady state response (ASSR) to click trains of stimuli at a frequency of 10–80 Hz. Fmr1-KO rats exhibited reduced basal alpha power and enhanced gamma power, and these rats showed enhanced locomotor activity in novel environment. While ASSR clearly peaked at around 40 Hz, both inter-trial coherence (ITC) and event-related spectral perturbation (ERSP) were significantly reduced at the gamma frequency band in Fmr1-KO rats. Fmr1-KO rats showed gamma power abnormalities and behavioral hyperactivity that were consistent with observations reported in mouse models and subjects with FXS. These results suggest that gamma power abnormalities are a translatable biomarker among species and demonstrate the utility of Fmr1-KO rats for investigating drugs for the treatment of FXS.
format Online
Article
Text
id pubmed-7608556
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76085562020-11-05 Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome Kozono, Naoki Okamura, Ai Honda, Sokichi Matsumoto, Mitsuyuki Mihara, Takuma Sci Rep Article Fragile X syndrome (FXS) is characteristically displayed intellectual disability, hyperactivity, anxiety, and abnormal sensory processing. Electroencephalography (EEG) abnormalities are also observed in subjects with FXS, with many researchers paying attention to these as biomarkers. Despite intensive preclinical research using Fmr1 knock out (KO) mice, an effective treatment for FXS has yet to be developed. Here, we examined Fmr1-targeted transgenic rats (Fmr1-KO rats) as an alternative preclinical model of FXS. We characterized the EEG phenotypes of Fmr1-KO rats by measuring basal EEG power and auditory steady state response (ASSR) to click trains of stimuli at a frequency of 10–80 Hz. Fmr1-KO rats exhibited reduced basal alpha power and enhanced gamma power, and these rats showed enhanced locomotor activity in novel environment. While ASSR clearly peaked at around 40 Hz, both inter-trial coherence (ITC) and event-related spectral perturbation (ERSP) were significantly reduced at the gamma frequency band in Fmr1-KO rats. Fmr1-KO rats showed gamma power abnormalities and behavioral hyperactivity that were consistent with observations reported in mouse models and subjects with FXS. These results suggest that gamma power abnormalities are a translatable biomarker among species and demonstrate the utility of Fmr1-KO rats for investigating drugs for the treatment of FXS. Nature Publishing Group UK 2020-11-02 /pmc/articles/PMC7608556/ /pubmed/33139785 http://dx.doi.org/10.1038/s41598-020-75893-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Kozono, Naoki
Okamura, Ai
Honda, Sokichi
Matsumoto, Mitsuyuki
Mihara, Takuma
Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
title Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
title_full Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
title_fullStr Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
title_full_unstemmed Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
title_short Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
title_sort gamma power abnormalities in a fmr1-targeted transgenic rat model of fragile x syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608556/
https://www.ncbi.nlm.nih.gov/pubmed/33139785
http://dx.doi.org/10.1038/s41598-020-75893-x
work_keys_str_mv AT kozononaoki gammapowerabnormalitiesinafmr1targetedtransgenicratmodeloffragilexsyndrome
AT okamuraai gammapowerabnormalitiesinafmr1targetedtransgenicratmodeloffragilexsyndrome
AT hondasokichi gammapowerabnormalitiesinafmr1targetedtransgenicratmodeloffragilexsyndrome
AT matsumotomitsuyuki gammapowerabnormalitiesinafmr1targetedtransgenicratmodeloffragilexsyndrome
AT miharatakuma gammapowerabnormalitiesinafmr1targetedtransgenicratmodeloffragilexsyndrome